Dan Jacobs, DO
Psychiatry · Fort Washington, PANPI 1831213263
Payments from drug & device makers
Across 964 payments — averaging $12.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Vanda Pharmaceuticals Inc.$830
- Takeda Pharmaceuticals U.S.A., Inc.$765
- plus $3K from 19 others
What the payments were for
- Food & beverage$11,44799%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 366 | $2,759 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 117 | $1,506 |
| Otsuka America Pharmaceutical, Inc. | 91 | $1,202 |
| Lundbeck LLC | 98 | $1,155 |
| Vanda Pharmaceuticals Inc. | 40 | $830 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $765 |
| Neurocrine Biosciences, Inc. | 40 | $713 |
| Sunovion Pharmaceuticals Inc. | 41 | $694 |
| Alkermes, Inc. | 32 | $475 |
| Johnson & Johnson | 21 | $350 |
| Teva Pharmaceuticals USA, Inc. | 14 | $305 |
| Axsome Therapeutics, Inc. | 7 | $154 |
| Eisai Inc. | 8 | $129 |
| Avanir Pharmaceuticals, Inc. | 7 | $125 |
| Idorsia Pharmaceuticals US Inc | 6 | $119 |
| Harmony Biosciences LLC | 2 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Shire North American Group Inc | 3 | $45 |
| Almatica Pharma LLC | 3 | $42 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Corium, LLC | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$11,579 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 59 | $105,970 |
| Invega SustennaPaliperidone Palmitate | 15 | $52,321 |
| VraylarCariprazine Hcl | 27 | $45,100 |
| Lurasidone Hcl | 41 | $11,196 |
| TrintellixVortioxetine Hydrobromide | 12 | $8,420 |
| BelsomraSuvorexant | 12 | $5,367 |
| Quetiapine Fumarate | 185 | $2,451 |
| Trazodone Hcl | 142 | $2,280 |
| Aripiprazole | 39 | $2,149 |
| Alprazolam | 313 | $1,558 |
| Clonazepam | 112 | $1,153 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $1,122 |
| Sertraline Hcl | 65 | $850 |
| Bupropion Hcl SrBupropion Hcl | 55 | $802 |
| Lorazepam | 80 | $771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,202 | $105,97059 claims |
| Johnson & JohnsonInvega Sustenna | $350 | $52,32115 claims |
| AbbVieVraylar | $2,759 | $45,10027 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $765 | $8,42012 claims |
| MerckBelsomra | $12 | $5,36712 claims |
| Almatica Pharma LLCSertraline Hcl | $42 | $85065 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Fort Washington
- Chand NairFort Washington$37K
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.